.jpeg)
2026-04-03 01:52:29
Adagrasib (brand name Krazati) is a highly selective oral KRAS G12C inhibitor, approved by the U.S. FDA for the treatment of KRAS G12C-mutated locally advanced/metastatic non-small cell lung cancer and colorectal cancer. It features excellent blood-brain barrier penetration and a long half-life, providing a precise anti-tumor option for patients with advanced solid tumors.
2026-04-02 05:08:01
This article provides a comprehensive analysis of the pharmacological effects, indicated populations, correct administration methods, contraindications, and medication safety precautions of aspirin enteric-coated tablets, offering standardized medication reference for populations at risk of cardiovascular and cerebrovascular diseases.
2026-04-01 04:22:07
Osimertinib (brand names Tagrisso/Tarceva), developed by AstraZeneca (UK), is a third-generation EGFR-TKI that selectively inhibits EGFR T790M, L858R, and exon 19 deletion mutations to block cancer cell signaling. It is widely used for EGFR-mutant non-small cell lung cancer (NSCLC).
2026-04-01 04:06:04
Published in The New England Journal of Medicineon March 25, 2026, the ATOMIC study by Dr. Frank A. Sinicrope’s team at Mayo Clinic demonstrated that atezolizumab combined with mFOLFOX6 chemotherapy significantly extended disease-free survival (DFS) in patients with dMMR stage III colon cancer, providing key evidence for immunotherapy applicability in this population.
2026-04-01 02:55:09
On April 1, 2026, the U.S. FDA granted accelerated approval to Kresladi (marnetegragene autotemcel), the first gene therapy for severe leukocyte adhesion deficiency type I (LAD-I), indicated for pediatric patients with biallelic ITGB2 variants and no available HLA-matched sibling donor for allogeneic hematopoietic stem cell transplantation.
2026-04-01 02:16:12
Cancer cells act as "rebellious agents" disrupting bodily harmony. Through global research advancements, we uncover the mechanisms of cancer formation, differences in types, and innovative therapies. From surgical removal to immunotherapy, scientific progress offers new hope. Dive into the mysteries of cancer and its future treatment prospects.
2026-03-31 02:36:04
This article dissects the fundamental differences between Dostarlimab (PD-1 inhibitor) and Secukinumab (IL-17A antagonist) across mechanisms, indications, efficacy metrics, and safety profiles, emphasizing their distinct roles in oncology and autoimmune diseases.
2026-03-30 07:09:03
Sunvozertinib, a next-gen EGFR-TKI, offers breakthrough efficacy for EGFR-mutated NSCLC patients. Designed to overcome resistance and tackle brain metastases, it provides a promising new option. Explore dosing guidelines, AE management, monitoring strategies, and long-term treatment insights.
2026-03-30 07:00:34
Lorlatinib, developed by Pfizer, is a groundbreaking third-generation ATP-competitive macrocyclic tyrosine kinase inhibitor targeting ALK and ROS1 mutations. With superior blood-brain barrier penetration and activity against resistant mutations, clinical data demonstrates unprecedented PFS超过3 years in frontline treatment, intracranial response rate of 83.3%, and transformative outcomes for advanced NSCLC patients. Explore its mechanism, global clinical evidence, administration guidelines, and AE management strategies.
2026-03-25 01:39:36
IRX4 as a transcription factor shows downregulated expression in colorectal cancer. Research reveals it can inhibit cancer cell proliferation and enhance chemotherapy sensitivity. This article analyzes IRX4 mechanisms and clinical application potential.
2026-03-25 01:28:42
Ponesimod (brand name PONVORY) is a selective S1P receptor modulator for treating adult relapsing multiple sclerosis. This article analyzes its mechanism, comparison with traditional medications, and safety features to assist patients and physicians in developing personalized treatment plans.
2026-03-24 04:46:55
Lemborexant (Dayvigo) is a dual orexin receptor antagonist for adult insomnia disorder treatment. This article details drowsiness, dizziness, sleep paralysis and other adverse reactions with monitoring points to help patients use medication safely.
